185 related articles for article (PubMed ID: 37482512)
21. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
22.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
23. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Performance and Clinical Impact of
Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
[TBL] [Abstract][Full Text] [Related]
25. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
[TBL] [Abstract][Full Text] [Related]
26. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
28. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Mehdi Irai M; Simon R; Koehler D; Rauscher I; Eiber M; van Leeuwen FWB; van Leeuwen P; de Barros H; van der Poel H; Budäus L; Steuber T; Graefen M; Tennstedt P; Heck MM; Horn T; Maurer T
Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
[TBL] [Abstract][Full Text] [Related]
29. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
[TBL] [Abstract][Full Text] [Related]
30. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH; Schilham M; Hermsen R; de Baaij JMS; Vrijhof HJEJ; Hoekstra RJ; Sedelaar JPM; Küsters-Vandevelde HVN; Gotthardt M; Wijers CHW; van Basten JP; Somford DM
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):65-70. PubMed ID: 34471231
[TBL] [Abstract][Full Text] [Related]
31. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
32. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract][Full Text] [Related]
33. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
34.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
35. A Comprehensive Assessment of
Abghari-Gerst M; Armstrong WR; Nguyen K; Calais J; Czernin J; Lin D; Jariwala N; Rodnick M; Hope TA; Hearn J; Montgomery JS; Alva A; Reichert ZR; Spratt DE; Johnson TD; Scott PJH; Piert M
J Nucl Med; 2022 Apr; 63(4):567-572. PubMed ID: 34326126
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of the performance of [
Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037
[TBL] [Abstract][Full Text] [Related]
37. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
Dekalo S; Kuten J; Mintz I; Fahoum I; Gitstein G; Keizman D; Sarid D; Matzkin H; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O; Mano R
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):910-916. PubMed ID: 33790418
[TBL] [Abstract][Full Text] [Related]
38. Administering [
Eapen RS; Buteau JP; Jackson P; Mitchell C; Oon SF; Alghazo O; McIntosh L; Dhiantravan N; Scalzo MJ; O'Brien J; Sandhu S; Azad AA; Williams SG; Sharma G; Haskali MB; Bressel M; Chen K; Jenjitranant P; McVey A; Moon D; Lawrentschuk N; Neeson PJ; Murphy DG; Hofman MS
Eur Urol; 2024 Mar; 85(3):217-226. PubMed ID: 37891072
[TBL] [Abstract][Full Text] [Related]
39. Prospective evaluation of
Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
[TBL] [Abstract][Full Text] [Related]
40. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
